量化头颈癌幸存者相关的总费用与自付费用
这项回顾性经济评价分析了2006至2018年美国IBM MarketScan商业理赔数据库中19098例头颈癌成人患者,评估诊断后13至60个月的总费用与自付费用较诊断前7至12个月基线的差异。结果显示,幸存期每月总费用和自付费用中位数分别较基线高372美元和31美元,女性、下咽癌和多模式治疗与更高的超额费用相关。作者建议临床医生尽量减少高危患者的费用负担并提供针对性支持服务。
要点
- 幸存期每月总费用和自付费用中位数分别较基线高372美元和31美元。
- 女性性别与更高的总费用(每月343美元)和自付费用(每月9美元)超额相关。
- 下咽癌的总超额幸存费用最高(每月1908美元),口咽癌最低(每月-703美元)。
核心结论
- 头颈癌幸存期费用在诊断后至少5年内持续高于基线费用。
- 高幸存费用与女性性别、下咽肿瘤和多模式治疗相关。
- 临床医生应尽量减少高危患者的费用负担并提供针对性支持服务。
研究设计与样本
- 回顾性审查和经济评价,队列为2006至2018年美国IBM MarketScan商业理赔数据库中诊断为头颈癌的成人。
- 样本量19098例,中位(范围)年龄56(18-64)岁,男性14144例(74.1%),女性4954例(25.9%),未考虑种族和族裔。
- 数据分析时间为2020年11月至2022年6月。
主要发现
- 幸存期(诊断后13-60个月)每月总费用和自付费用中位数分别较基线(诊断前7-12个月)高372美元和31美元。
- 多变量模型中,女性与更高的总费用(每月343美元;95%CI,126至560美元)和自付费用(每月9美元;95%CI,4至14美元)超额幸存费用相关。
- 与口腔癌相比,下咽癌的总超额幸存费用最高(每月1908美元;95%CI,1102至2714美元),口咽癌最低(每月-703美元;95%CI,-967至-439美元)。
- 与单独手术或放疗相比,多模式治疗通常与超额自付幸存费用相关。
关键数值与推荐
- 主要结局为患者平均每月幸存费用(诊断后13-60个月)与平均每月基线费用(诊断前7-12个月)的差值。
临床怎么用
- 作者建议,临床医生应尽量减少治疗后财务毒性高风险患者的费用,并努力提供针对性支持服务。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Oncologic treatment is costly to the health care system and to individuals, but patients with head and neck cancer (HNC) also have long-term care needs after treatment. Survivors of HNC require specific consideration given their rapidly growing numbers. This subpopulation of cancer survivors often experiences long-term treatment-associated morbidity. OBJECTIVE: To describe the total and out-of-pocket (OOP) costs associated with HNC survivorship and the risk factors for financial toxicity among this population. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective review and economic evaluation of a cohort of US adults with a diagnosis of HNC from 2006 to 2018. The study used data the from IBM MarketScan Commercial Claims Database. Data were analyzed from November 2020 to June 2022. EXPOSURES: Treatment for HNC. MAIN OUTCOMES AND MEASURES: Total and OOP medical costs were assessed monthly and reported relative to the date of HNC diagnosis. The primary outcome was the difference between a patient's mean monthly survivorship costs (13-60 months after diagnosis) and mean monthly baseline costs (7-12 months before diagnosis). Univariate and multivariable linear regression models were created for total and OOP costs to generate coefficient estimates with 95% CIs. RESULTS: The study cohort of this economic evaluation included 19 098 patients with HNC (median [range] age, 56 [18-64] years; 14 144 [74.1%] men and 4954 [25.9%] women; race and ethnicity were not considered). Throughout the survivorship period, median total and OOP costs were $372 per month and $31 per month higher than baseline costs, respectively, with variation in expenses by demographic information, health plan type, and oncologic variables. In the multivariable model, greater total and OOP excess survivorship costs were associated with female sex ($343/mo; 95% CI, $126 to $560 and $9/mo; 95% CI, $4 to $14). Highest and lowest total excess survivorship costs associated with cancer site were seen for hypopharyngeal ($1908/mo; 95% CI, $1102 to $2714) and oropharyngeal cancers (-$703/mo; 95% CI, -$967 to -$439) vs oral cavity cancers. Compared with surgery or radiation therapy alone, multimodal treatment was generally associated with excess OOP survivorship costs. CONCLUSIONS AND RELEVANCE: The findings of this retrospective economic evaluation review suggest that the costs of HNC survivorship remain persistently elevated above baseline costs for at least 5 years after diagnosis. High survivorship costs were associated with female sex, hypopharyngeal tumors, and treatment with multimodal therapy. Practitioners should seek to minimize costs for these patients at higher-risk of financial toxicity after treatment and work to provide directed supportive services.
引用
- Massa ST, Chidambaram S, Luong P, et al. Quantifying Total and Out-of-Pocket Costs Associated With Head and Neck Cancer Survivorship. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 36264567. doi:10.1001/jamaoto.2022.3269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。